Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an ultra-long-acting factor VIII simplify surgery for hemophilia a patients?

NCT ID NCT07723560

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study collects real-world data on how hemophilia A patients are managed during and after surgery when using efanesoctocog alfa (Altuvoct), a long-acting clotting factor. Researchers will track how much of the drug is needed, how often it is given, and how long patients stay in the hospital. The goal is to compare these results with those from an older clotting factor and help standardize surgical care across centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
efanesoctocog alfa (Altuvoct), a long-acting factor VIII replacement therapy
What this could lead to
If successful, this study could help standardize surgical protocols for hemophilia A patients using ultra-long-acting factor VIII, potentially improving outcomes and reducing variability across hospitals.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary widely due to differences in surgical procedures and patient characteristics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes adult and pediatric patients with Hemophilia A undergoing surgical procedures.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hemophilia A * Surgery performed with Altuvoct® * Patient consent to participate after receiving detailed written information. Exclusion Criteria: * Presence of any blood coagulation disorder other than hemophilia A. * Detectable factor VIII inhibitors. * Known severe liver disease. * Known severe kidney disease. * Known hypersensitivity to Altuvoct® or any of its excipients. * Participation in another clinical trial (participation in non-interventional studies is not an exclusion criterion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Factor viii are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Factor viii Haemophilia A

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Unité d'Hémostase Clinique Centre Régional de Traitement des Hémophiles Centre de Référence de Maladies Hémorragiques Hôpital Cardiologique Louis Pradel

    RECRUITING

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.